The Scripps Research Institute

Plexium, Inc.

California Institute of Technology

Raythera, Inc.

Pengyu Yang

Peter G Schultz

Weijun Shen

Huafei Zou

Kandaswamy Vijayan

Yi Zhang

Chanhyuk Kim

Jiayin Shen

Jesse Lu

Avinash Muppidi

Jennifer Ma

Jun Y Axup

Insha Ahmad

Alex Price

Hwayoung Yun

Qing Dong

Junhu Zhang

Simon Bailey

Mark Wilson

Venkat Bollu

Lynnie Trzoss

Andreas Crameri

Described herein are modulators of TNF alpha activity and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TNF alpha-mediated disorders or diseases.

Modulators of TNF alpha activity and uses thereof

Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Disclosed is an assay device comprising a high density of wells aligned thereon.

Assay devices for combinatorial libraries

Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compounds are of formula I:

Aryl compounds and pharmaceutical compositions that modulate IKZF2

Disclosed are substituted quinazolinone compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions such as those relating to unregulated protein function and/or levels.

Quinazolinone compounds and related compounds

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.

Targeting agent antibody conjugates and uses thereof

Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

Modified therapeutic agents and compositions thereof

Growing community of inventors

San Diego, CA, United States of America

Pengyu Yang